Marbofloxacin
Sold as Zeniquin, Marbocyl, Forcyl, Marbocyl palatable
7-Fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
Drag to rotate. Structure from PubChem CID 60651.
Background
Registration
- Applicants
- 2
- Registrations
- 9
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Zoetis South Africa (Pty) Ltd1 of 4 cancelled | Zeniquin | 25, 50, 100, 200 | 02/01, 02/02, 02/03, 4-Feb | S4 | None |
| Vetpharma (Pty) Ltd | Marbocyl, Forcyl, Marbocyl palatable | 5 mg, 10 %, 16 %, 20 mg, 80 mg | 06/07, 19/25, 21/20, 21/21, 21/22 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Zeniquin 25 EACH TABLET CONTAINS:MARBOFLOXACIN 25,0 mg | 25 | 02/0102/21.9/1 | Registered | S4 | None |
| Zeniquin 50 EACH TABLET CONTAINS:MARBOFLOXACIN 50,0 mg | 50 | 02/0202/21.9/2 | Registered | S4 | None |
| Zeniquin 100 EACH TABLET CONTAINS:MARBOFLOXACIN 100,0 mg | 100 | 02/0302/21.9/3 | Registered | S4 | None |
| Marbocyl 10 % EACH 1,0 ml SOLUTION CONTAINS:MARBOFLOXACIN 100,0 mg | 10 % | 06/0706/17.1.6/07 | Registered | S4 | None |
| Forcyl 16 % solution for injection EACH 1,0 ml SOLUTION CONTAINS:MARBOFLOXACIN 160,0 mg | 16 %Solution for injection | 19/2519/17.1.6/25 | Registered | S4 | None |
| Marbocyl palatable 5 MG tablets Each tablet contains: Marbofloxacin 5 mg | 5 mgTablets | 21/2021/17.1.6/20 | Registered | S4 | None |
| Marbocyl palatable 20 MG tablets Each tablet contains :Marbofloxacin 20 mg | 20 mgTablets | 21/2121/17.1.6/21 | Registered | S4 | None |
| Marbocyl palatable 80 MG tablets Each Tablet contains: Marbofloxacin 80 mg | 80 mgTablets | 21/2221/17.1.6/22 | Registered | S4 | None |
| Zeniquin 200 EACH TABLET CONTAINS MARBOFLOXACIN 200,0 mg | 200 | 4-Feb02/21.9/4 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Marbofloxacin
S4: Marbofloxacin
Consolidated Schedules 06 July 2026, line 7006
Pharmacological class: Androgen-oestrogen combinations. (class 21.9)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.